View in EDS

Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.

Saved in:
Bibliographic Details
Title: Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.
Authors: Haidar G; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: haidarg@upmc.edu., Thomas S; Biometrics, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Chiesi USA, Cary, NC, USA., Loubet P; Service des Maladies Infectieuses et Tropicales, CHU Nîmes Carémeau, Université de Montpellier, Nîmes, France., Baker RI; Western Australia Centre for Thrombosis and Haemostasis, Murdoch University, Perth, WA, Australia; Clinical Research Unit, Perth Blood Institute, Perth, WA, Australia; Hollywood Hospital Haemophilia Centre, Haematology Academic Unit, Perth, WA, Australia., Benfield T; Department of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark., Boonyaratanakornkit J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Department of Medicine, University of Washington, Seattle, WA, USA., Kiertiburanakul S; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Kim AHJ; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA., Longbrake EE; Department of Neurology, Yale School of Medicine, New Haven, CT, USA., Molina JM; University of Paris Cité, INSERM U944, Hôpital Saint-Louis, Lariboisière Hospitals, Assistance Publique Hopitaux de Paris, Paris, France., Paredes R; Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Department of Infectious Diseases and IrsiCaixa, University Hospital Germans Trias i Pujol, Barcelona, Spain., Tucker D; Haematology Research Department, Haematology Clinic, Royal Cornwall Hospital NHS Trust, Truro, UK., Uriel A; Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital (Manchester University NHS Foundation Trust), Manchester, UK., Weinmann-Menke J; First Department of Medicine and Research Center for Immunotherapy, University Medical Center of the Johannes Gutenberg University, Mainz, Germany., Aksyuk AA; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA., Clegg LE; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA., Currie A; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK., Yang H; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA., Flyrin K; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Mölndal, Sweden., Gibbs M; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK., Shroff M; Patient Safety, Chief Medical Office, Research & Development, AstraZeneca, Waltham, MA, USA., Perez JL; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA., Chang LJ; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA., Cohen TS; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA. Electronic address: taylor.cohen@astrazeneca.com.
Corporate Authors: SUPERNOVA study group
Source: The Lancet. Infectious diseases [Lancet Infect Dis] 2025 Jul; Vol. 25 (7), pp. 813-826. Date of Electronic Publication: 2025 Feb 24.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40015292
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Haidar+G%22">Haidar G</searchLink>; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: haidarg@upmc.edu.<br /><searchLink fieldCode="AU" term="%22Thomas+S%22">Thomas S</searchLink>; Biometrics, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Chiesi USA, Cary, NC, USA.<br /><searchLink fieldCode="AU" term="%22Loubet+P%22">Loubet P</searchLink>; Service des Maladies Infectieuses et Tropicales, CHU Nîmes Carémeau, Université de Montpellier, Nîmes, France.<br /><searchLink fieldCode="AU" term="%22Baker+RI%22">Baker RI</searchLink>; Western Australia Centre for Thrombosis and Haemostasis, Murdoch University, Perth, WA, Australia; Clinical Research Unit, Perth Blood Institute, Perth, WA, Australia; Hollywood Hospital Haemophilia Centre, Haematology Academic Unit, Perth, WA, Australia.<br /><searchLink fieldCode="AU" term="%22Benfield+T%22">Benfield T</searchLink>; Department of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark.<br /><searchLink fieldCode="AU" term="%22Boonyaratanakornkit+J%22">Boonyaratanakornkit J</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Department of Medicine, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Kiertiburanakul+S%22">Kiertiburanakul S</searchLink>; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.<br /><searchLink fieldCode="AU" term="%22Kim+AHJ%22">Kim AHJ</searchLink>; Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.<br /><searchLink fieldCode="AU" term="%22Longbrake+EE%22">Longbrake EE</searchLink>; Department of Neurology, Yale School of Medicine, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Molina+JM%22">Molina JM</searchLink>; University of Paris Cité, INSERM U944, Hôpital Saint-Louis, Lariboisière Hospitals, Assistance Publique Hopitaux de Paris, Paris, France.<br /><searchLink fieldCode="AU" term="%22Paredes+R%22">Paredes R</searchLink>; Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Department of Infectious Diseases and IrsiCaixa, University Hospital Germans Trias i Pujol, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Tucker+D%22">Tucker D</searchLink>; Haematology Research Department, Haematology Clinic, Royal Cornwall Hospital NHS Trust, Truro, UK.<br /><searchLink fieldCode="AU" term="%22Uriel+A%22">Uriel A</searchLink>; Department of Infectious Diseases and Tropical Medicine, North Manchester General Hospital (Manchester University NHS Foundation Trust), Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Weinmann-Menke+J%22">Weinmann-Menke J</searchLink>; First Department of Medicine and Research Center for Immunotherapy, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Aksyuk+AA%22">Aksyuk AA</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Clegg+LE%22">Clegg LE</searchLink>; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Currie+A%22">Currie A</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Yang+H%22">Yang H</searchLink>; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Flyrin+K%22">Flyrin K</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Mölndal, Sweden.<br /><searchLink fieldCode="AU" term="%22Gibbs+M%22">Gibbs M</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Shroff+M%22">Shroff M</searchLink>; Patient Safety, Chief Medical Office, Research & Development, AstraZeneca, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Perez+JL%22">Perez JL</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Chang+LJ%22">Chang LJ</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Cohen+TS%22">Cohen TS</searchLink>; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA. Electronic address: taylor.cohen@astrazeneca.com.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22SUPERNOVA+study+group%22">SUPERNOVA study group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101130150%22">The Lancet. Infectious diseases</searchLink> [Lancet Infect Dis] 2025 Jul; Vol. 25 (7), pp. 813-826. <i>Date of Electronic Publication: </i>2025 Feb 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101130150 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-4457 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214733099%22">14733099 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Infect Dis <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40015292
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1473-3099(24)00804-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 813
    Titles:
      – TitleFull: Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Haidar G
      – PersonEntity:
          Name:
            NameFull: Thomas S
      – PersonEntity:
          Name:
            NameFull: Loubet P
      – PersonEntity:
          Name:
            NameFull: Baker RI
      – PersonEntity:
          Name:
            NameFull: Benfield T
      – PersonEntity:
          Name:
            NameFull: Boonyaratanakornkit J
      – PersonEntity:
          Name:
            NameFull: Kiertiburanakul S
      – PersonEntity:
          Name:
            NameFull: Kim AHJ
      – PersonEntity:
          Name:
            NameFull: Longbrake EE
      – PersonEntity:
          Name:
            NameFull: Molina JM
      – PersonEntity:
          Name:
            NameFull: Paredes R
      – PersonEntity:
          Name:
            NameFull: Tucker D
      – PersonEntity:
          Name:
            NameFull: Uriel A
      – PersonEntity:
          Name:
            NameFull: Weinmann-Menke J
      – PersonEntity:
          Name:
            NameFull: Aksyuk AA
      – PersonEntity:
          Name:
            NameFull: Clegg LE
      – PersonEntity:
          Name:
            NameFull: Currie A
      – PersonEntity:
          Name:
            NameFull: Yang H
      – PersonEntity:
          Name:
            NameFull: Flyrin K
      – PersonEntity:
          Name:
            NameFull: Gibbs M
      – PersonEntity:
          Name:
            NameFull: Shroff M
      – PersonEntity:
          Name:
            NameFull: Perez JL
      – PersonEntity:
          Name:
            NameFull: Chang LJ
      – PersonEntity:
          Name:
            NameFull: Cohen TS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2025 Jul
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1474-4457
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: The Lancet. Infectious diseases
              Type: main
ResultId 1